FDA panel backs Galleri blood test that screens for more than 50 cancers


Full story

A blood test designed to screen for dozens of cancers at once just received a major boost from a U.S. Food and Drug Administration advisory panel.

In a 7-2 vote Wednesday, the FDA advisory panel found that the DNA-based test offers more potential benefits than risks, while noting that questions about the technology still require further study.

QR code for SAN app download

Download the Straight Arrow app today to get the stories that matter free from manipulation, bias or agenda.™

Point phone camera here

“Perhaps my yes is a hopeful rather than an accurate one,” one of the panelists said, according to The Associated Press. “If we can find more early-stage cancers in the population that we can’t screen for currently, that will end up having benefit.”

Despite the need for more research, the test could give doctors a new way to detect cancers that currently have no routine screening, should the FDA follow the panel’s recommendation.

The Galleri test

The Galleri test is intended for people 50 and older.

With a single blood draw, it looks for DNA signals linked to more than 50 types of cancer. If the test comes back positive, patients still need additional testing to determine whether cancer is actually present.

In a large study of more than 140,000 people, it detected about one-third of the cancers that were eventually diagnosed.

But there are limitations.

The test was much better at finding later-stage cancers than early ones, and FDA reviewers worry a negative result could give some people false reassurance and lead them to skip routine screenings. That’s why the panel backed the test as an additional option, rather than a replacement for existing cancer screenings.

What happens next

Galleri is already available in the U.S., but it’s not FDA-approved, and patients generally have to pay for it themselves. FDA approval could make insurance coverage more likely.

The FDA doesn’t have to follow the panel’s recommendation and hasn’t said when it will make a final decision.

Round out your reading

Tags: , , ,

Straight Arrow
Fear No Fact.™

Don't just take our word for it.


Center-rated reporting

According to media bias experts at AllSides

AllSides Center-rated reporting May 2026

Transparent and credible

Awarded a perfect reliability rating from NewsGuard

100/100

Welcome back to trustworthy journalism.

Find out more

Why this story matters

A blood test that screens for more than 50 cancer types at once moved closer to FDA approval, which could affect how Americans 50 and older are screened and whether insurance covers the cost.

Coverage may follow approval

Galleri is currently available but not FDA-approved, meaning patients generally pay out of pocket; full approval could make insurance coverage more likely, according to the article.

Test has documented limits

In a large study, the test detected about one-third of cancers eventually diagnosed and performed better at finding later-stage cancers than early ones.

Not a replacement screening

The advisory panel approved the test as an additional option, not a substitute, citing concern that a negative result could lead people to skip routine screenings.

Straight Arrow
Fear No Fact.™

Don't just take our word for it.


Center-rated reporting

According to media bias experts at AllSides

AllSides Center-rated reporting May 2026

Transparent and credible

Awarded a perfect reliability rating from NewsGuard

100/100

Welcome back to trustworthy journalism.

Find out more